Company news
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) news
Eton Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 28, 2026: Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine)…
Press releases & updates
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
September 28, 2026
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
August 27, 2026
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 13, 2026
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
August 5, 2026
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
August 3, 2026
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI Oral Solution
July 30, 2026
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
July 29, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 18, 2026
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
May 14, 2026
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
May 12, 2026
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 4, 2026
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
May 1, 2026
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
April 27, 2026
Eton Pharmaceuticals Announces CFO Succession Plan
April 15, 2026
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 18, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 3, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
March 2, 2026
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
February 25, 2026
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
February 20, 2026
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
February 2, 2026
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
November 23, 2025
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
November 11, 2025
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 5, 2025
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
October 22, 2025
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
August 19, 2025
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 6, 2025
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
July 27, 2025
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
July 7, 2025
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
June 26, 2025
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
May 27, 2025
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
May 13, 2025
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
May 12, 2025
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
April 30, 2025
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
April 27, 2025
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
March 31, 2025
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
March 17, 2025
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
March 13, 2025
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
March 3, 2025
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
March 2, 2025
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
February 6, 2025
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
February 5, 2025
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
January 2, 2025
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
December 19, 2024
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
December 16, 2024
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
December 2, 2024
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
November 24, 2024
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 11, 2024
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
November 6, 2024
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 5, 2024
SWK Holdings Provides Portfolio Update
October 16, 2024